TY  - JOUR
A1  - Kuçi, Zyrafete
A1  - Jordan, Christiane
A1  - Wehner, Sibylle
A1  - Sörensen, Jan
A1  - Jarisch, Andrea
A1  - Salzmann-Manrique, Emilia
A1  - Pfeffermann, Lisa-Marie
A1  - Klingebiel, Thomas
A1  - Bader, Peter
A1  - Kuçi, Selim
T1  - The phenotype and functional activity of mesenchymal stromal cells in pediatric patients with non-malignant hematological disease
T2  - Cells
N2  - As the biology of mesenchymal stromal cells (MSCs) in patients with non-malignant hematological diseases (NMHD) is poorly understood, in the current study we performed a basic characterization of the phenotype and functional activity of NMHD-MSCs. Bone marrow (BM) of patients with thalassemia major (TM) possessed a significantly higher number of nucleated cells (BM-MNCs)/mL BM than healthy donors (P < 0.0001), which however did not result in a higher number of colony forming units-fibroblast (CFU-F) per milliliter BM. In contrast, from 1 × 106 BM-MNCs of patients with sickle cell disease (SCD) were generated significantly more CFU-Fs than from TM-BM-MNCs (P < 0.013) and control group (P < 0.02). In addition, NMHD-MSCs expressed significantly lower levels of CD146 molecule, demonstrated an equal proliferation potential and differentiated along three lineages (osteoblasts, chondrocytes and adipocytes) as healthy donors’ MSCs, with exception of TM-MSCs which differentiated weakly in adipocytes. In contrast to other NMHD-MSCs and healthy donors’ MSCs, TM-MSCs demonstrated an impaired in vitro immunosuppressive potential, either. Noteworthy, the majority of the immunosuppressive effect of NMHD-MSCs was mediated through prostaglandin-E2 (PGE2), because indomethacin (an inhibitor of PGE2 synthesis) was able to significantly reverse this effect. Our results indicate therefore that NMHD-MSCs, except TM-MSCs, may be used as an autologous cell-based therapy for post-transplant complications such as graft failure, graft-versus-host disease (GvHD) and osteonecrosis.
KW  - mesenchymal stromal cells
KW  - non-malignant hematological diseases
KW  - thalassemia
KW  - sickle cell anemia
KW  - severe congenital neutropenia
Y1  - 2020
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/54422
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-544229
N1  - This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
VL  - 9
IS  - 431
PB  - MDPI
CY  - Basel
ER  -